INS and Hypoglycemia: The SWITCH-1 trial also reported that the cost of treatment with insulin degludec was higher compared to insulin glargine U100, however, treatment with insulin degludec was more cost-effective as a result of the reduction in the rates of nocturnal and severe hypoglycemia (Evans et al., 2018).